Longeveron rises as it wins China patent for stem cell test
08/04/2026 14:26
** Longeveron LGVN.O shares rise 6% to $1.23 premarket ** Biotech firm says secured a patent in China covering tests that measure the strength and quality of its stem cell products, expanding its global patent protection ** The patent, valid through 2041, covers potency tests for mesenchymal stem cells, which are adult stem cells used to help repair tissue and reduce inflammation - LGVN ** Adds that the tests apply to stem cells derived from bone marrow, fat, blood, organs and lab-made stem cells, helping ensure safety and effectiveness of therapies ** Says the patent adds to its international portfolio of 52 patents ** Longeveron’s lead experimental therapy is being tested in Alzheimer’s disease, rare pediatric heart disease and age-related frailty ** As of last close, stock has nearly doubled YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))